Research programme: alpha synuclein inhibitors- EnterinAlternative Names: ENT 01; Enterin-01; kenterin
Latest Information Update: 23 Feb 2017
At a glance
- Originator Enterin
- Class Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Constipation
Most Recent Events
- 03 Feb 2017 Preclinical trials in Constipation in USA (PO) (Enterin pipeline, February 2017)
- 03 Feb 2017 Enterin plans a phase I/IIa trial for Constipation in USA (NCT03047629)